Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients

Transplant International

Volumn 11, Issue SUPPL. 1, 1998, Pages

  Ginevri, F ^a   Losurdo, G ^a   Fontana, I ^b   Rabagliati, A M ^a   Bonatto, L ^a   Valente, R ^b   Venzano, P ^a   Nocera, A ^b   Basile, G C ^a   Valente, U ^b   Gusmano, R ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

CMV prophylaxis; CMV therapy; Cytomegalovirus infection; Kidney transplant; Pediatric recipients

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; KIDNEY TRANSPLANTATION; MALE; PRESCHOOL CHILD; RISK FACTOR; TIME;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; MALE; RISK FACTORS; TIME FACTORS;

EID: 0031614193     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.1998.tb01096.x     Document Type: Article

References (31)

1. Ho M (1990) Epidemiology of cytomegalovirus infections. Rev Infect Dis 12: S701-S710
2. Weir MR, Irwin BC, Maters AW, Genemans G, Shen SY, Charache P, Williams GM (1987) Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. Transplantation 43: 187-193
3. Rubin RH (1994) Infection in the organ transplant patient. In: Rubin RH, Young LS (eds) Clinical approach to infection in the compromised host. Plenum Medical Books, New York, pp 629-705
4. Mustafa MM (1994) Cytomegalovirus infection and disease in the immunocompromised host. Pediatr Infect Dis J 13: 249-259
5. Hirata M, Terasaki PI, Cho YW (1996) Cytomegalovirus antibody status and renal transplantation: 1987-1994. Transplantation 62: 34-37
6. Snydman DR, Rubin RH, Werner BG (1993) New developments in cytomegalovirus prevention and management. Am J Kidney Dis 21: 217-228
7. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K (1990) Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 12: S827-S838
8. Snydman DR (1993) Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients. Transplant Proc 125: S25-S26
9. Conti DJ, Freed BM, Lempert N (1993) Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant Proc 25: 1421-1422
10. Glowacki LS, Smaill FM (1993) Metaanalysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplant Proc 25: 1408-1410
11. Legendre C, Ducloux D, Ferroni A, Chkoff N, Valette C, Geffrier C, Rouzioux C, Kreis H (1993) Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. Transplant Proc 25: 1431-1433
12. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R (1996) Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 7: 325-330
13. Goral S, Ynares C, Dummer S, Helderman JH (1996) Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective? Kidney Int 50: S62-S65
14. Son WJ van, Berg AP van den, The TH, Tegzess AM (1993) Preemptive therapy with ganciclovir for early high-risk CMV infection allows effective treatment with antihymocyte globulin of steroid-resistant rejection after renal transplantation. Transplant Proc 25: 1436-1438
15. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, Snydman DR, Freeman R, Lorber MI, Rubin RH (1995) Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 123: 18-26
16. Winston DJ (1995) Prevention of cytomegalovirus disease in transplant recipients (commentary). Lancet 346: 25
17. Crumpacker CS (1996) Drug therapy: ganciclovir. N Engl J Med 335: 721-729
18. Bij W van der, Torensma R, Son WJ van, Anema J, Schirm J, Tegzess AM, The TH (1988) Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 25: 179-188
19. The TH, Ploeg M van der, Berg AP van den, Vlieger AM, Giessen van der, Son WJ van (1992) Direct detection of cytomegalovirus in peripheral blood leukocytes. A review of the antigenemia assay and polymerase chain reaction. Tansplantation 54: 193-198
20. Halwachs G, Zach R, Pogglitsch H, Holzer H, Tiran A, Iberer F, Wasler A, Tscheliessnigg HP, Lanzer G, Fölsch B, Wilders-Truschnig M (1993) A rapid immunocytochemical assay for CMV detection in peripheral blood of organtransplanted patients in clinical practice. Transplantation 56: 338-342
21. Murray BM, Brentjens J, Amsterdam D, Myers J, Gray V, Pawlowski I, Schewegler K, Sing JP, Venuto RC (1994) The cytomegalovirus-antigenemia assay in the diagnosis of post-transplant cytomegalovirus infection. J Am Soc Nephrol 4: 1615-1622
22. Pouteil-Noble C, Ecochard R, Landrivon G, Donia-Maged A, Tardy JC, Bosshard S, Colon S, Betuel H, Aymard M, Touraine JL (1993) Cytomegalovirus infection - an etiological factor for rejection? Transplantation 55: 851-857
23. Murray B, Blas S, Venuto R, Myers J, Amsterdam D (1996) Relapsing cytomegalovirus infection: etiology and consequences (abstract). J Am Soc Nephrol 7: 1937
24. Hornef MW, Bein G, Fricke L, Steinhoff J, Wagner HJ, Hinderer W, Sonneborn HH, Kirchner H (1995) Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection and rejection episodes in renal transplant recipients. Transplantation 60: 474-480
25. Carrieri G, Jordan ML, Shapiro R, Scantlebury VP, Vivas C, Kusne S, Magnone M, McCauley J, Starzl TE (1995) Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients. Transplant Proc 27: 961-963
26. Uber L, Cofer J, Baliga P, Rajagopalan PR (1995) Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient. Transplant Proc 27: S42-S43
27. Winston DJ, Ho WG, Bartoni K, Mond C du, Ebeling DF, Buhles WC, Champlin RE (1993) Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogenic bone marrow transplant recipients. Results of a placebo-controlled double-blind trial. Ann Intern Med 118: 179-184
28. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JC (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogenic marrow transplant. An Intern Med 118: 173-178
29. Winston DJ, Wirin D, Shaked A, Busuttil RW (1995) Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 346: 69-74
30. Nasimul A, Holman MJ, Dhilon S, Ream L, Yang HC (1996) Oral ganciclovir (Cytovene) effectively prevents cytomegalovirus (CMV) infection in renal transplant patients (abstract). J Am Soc Nephrol 7: 1929
31. Singer GG, Storch GA, Burton G, Lippmann BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Shenoy S, Howard TK, Brennan DC (1996) Prophylactic oral ganciclovir prevents cytomegalovirus disease in high-risk renal transplant recipients (abstract). J Am Soc Nephrol 7: 1941